#news #biotech Bayer pays $400M upfront to buy into Loxo cancer drugs

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Bayer pays $400M upfront to buy into Loxo cancer drugs .Bayer has paid $400 million (€340 million) and committed to more than $1 billion more to buy into Loxo Oncology’s tropomyosin receptor kinase inhibitor franchise. The agreement puts Bayer in charge of global commercialization of a drug that chalked up a 75% response rate in a midphase trial.

from FierceBiotech: Biotech http://ift.tt/2AFehc5